biostudies-literatureUnknown119(2)Dupuis F<h4>Background</h4>Prescribing anti-programmed death-1 (PD-1) immunotherapy for advanced melanoma is currently not restricted by any biomarker assessment. Determination of programmed death-ligand-1 (PD-L1)-expression status is technically challenging and is not mandatory, because negative tumours also achieve therapeutic responses. However, reproducible biomarkers predictive of a response to anti-PD-1 therapy could contribute to improving therapeutic decision-making.<h4>Methods</h4>This retrospective study on 70 metastatic melanoma patients was undertaken to evaluate the relationships between clinical, histological, immunohistochemical and/or molecular criteria, and the 6-month objective response rate.<h4>Results</h4>Better objective response rates were associated with metachronous metastases (P = 0.04), PD-L1 tumour- and/or immune-cell status (P = 0.01), CD163+ histiocytes at advancing edges (P = 0.009) of primary melanomas and NRAS mutation (P = 0.019). Moreover, CD163+ histiocytes at advancing edges (P = 0.04) were associated with longer progression-free survival (PFS), and metachronous metastases with longer overall survival (P = 0.02) and PFS (P = 0.049).<h4>Conclusions</h4>Combining these reproducible biomarkers could help improve therapeutic decision-making for patients with progressive disease.British journal of cancer193-199https://www.ebi.ac.uk/biostudies/studies/S-EPMC6048096biostudies-literatureClinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.PMC6048096Vergier BBeylot-Barry MJullie MLMeyer NDupuis FPrey STorossian NGros AGerard EFilleron TChaltiel LLamant LDutriaux CfalseClinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.<h4>Background</h4>Prescribing anti-programmed death-1 (PD-1) immunotherapy for advanced melanoma is currently not restricted by any biomarker assessment. Determination of programmed death-ligand-1 (PD-L1)-expression status is technically challenging and is not mandatory, because negative tumours also achieve therapeutic responses. However, reproducible biomarkers predictive of a response to anti-PD-1 therapy could contribute to improving therapeutic decision-making.<h4>Methods</h4>This retrospective study on 70 metastatic melanoma patients was undertaken to evaluate the relationships between clinical, histological, immunohistochemical and/or molecular criteria, and the 6-month objective response rate.<h4>Results</h4>Better objective response rates were associated with metachronous metastases (P = 0.04), PD-L1 tumour- and/or immune-cell status (P = 0.01), CD163+ histiocytes at advancing edges (P = 0.009) of primary melanomas and NRAS mutation (P = 0.019). Moreover, CD163+ histiocytes at advancing edges (P = 0.04) were associated with longer progression-free survival (PFS), and metachronous metastases with longer overall survival (P = 0.02) and PFS (P = 0.049).<h4>Conclusions</h4>Combining these reproducible biomarkers could help improve therapeutic decision-making for patients with progressive disease.2018-01-01T00:00:00Z2018 Jul2024-11-15T20:47:58.257Z2019-07-24T07:31:50ZS-EPMC60480962997367010.1038/s41416-018-0168-9